DK2139987T5 - Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser - Google Patents

Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser

Info

Publication number
DK2139987T5
DK2139987T5 DK08746528.2T DK08746528T DK2139987T5 DK 2139987 T5 DK2139987 T5 DK 2139987T5 DK 08746528 T DK08746528 T DK 08746528T DK 2139987 T5 DK2139987 T5 DK 2139987T5
Authority
DK
Denmark
Prior art keywords
senescen
relations
procedures
protein preparation
protein
Prior art date
Application number
DK08746528.2T
Other languages
English (en)
Other versions
DK2139987T3 (da
Inventor
Yen-Tung Luan
Gregory Walter Hiller
Wenge Wang
Jose Manuel Gomes
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39493848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2139987(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of DK2139987T3 publication Critical patent/DK2139987T3/da
Application granted granted Critical
Publication of DK2139987T5 publication Critical patent/DK2139987T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08746528.2T 2007-04-23 2008-04-22 Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser DK2139987T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91338207P 2007-04-23 2007-04-23
PCT/US2008/061125 WO2008131375A1 (en) 2007-04-23 2008-04-22 Methods of protein production using anti-senescence compounds

Publications (2)

Publication Number Publication Date
DK2139987T3 DK2139987T3 (da) 2013-09-02
DK2139987T5 true DK2139987T5 (da) 2014-01-27

Family

ID=39493848

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08746528.2T DK2139987T5 (da) 2007-04-23 2008-04-22 Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
DK08746526.6T DK2139986T3 (da) 2007-04-23 2008-04-22 Anvendelse af lav temperatur og/eller lav pH-værdi i cellekultur

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08746526.6T DK2139986T3 (da) 2007-04-23 2008-04-22 Anvendelse af lav temperatur og/eller lav pH-værdi i cellekultur

Country Status (26)

Country Link
US (2) US9988662B2 (da)
EP (2) EP2139986B1 (da)
JP (3) JP5557736B2 (da)
KR (3) KR101540124B1 (da)
CN (3) CN105039473A (da)
AR (2) AR066238A1 (da)
AU (2) AU2008242632B2 (da)
BR (2) BRPI0810511A2 (da)
CA (2) CA2685552C (da)
CL (2) CL2008001159A1 (da)
CO (2) CO6241165A2 (da)
DK (2) DK2139987T5 (da)
ES (2) ES2424217T3 (da)
HK (2) HK1142095A1 (da)
HU (1) HUE034776T2 (da)
IL (2) IL201720A (da)
MX (2) MX2009011363A (da)
PA (2) PA8777701A1 (da)
PE (2) PE20090731A1 (da)
PL (2) PL2139986T3 (da)
PT (2) PT2139986T (da)
RU (2) RU2478702C2 (da)
SI (2) SI2139987T1 (da)
TW (2) TW200902708A (da)
WO (2) WO2008131374A1 (da)
ZA (1) ZA200907426B (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174804A1 (da) 2006-09-13 2011-10-28 Abbott Lab
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
EP2188371B1 (en) 2007-08-09 2017-12-20 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
AU2009347206C1 (en) * 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
SG10201702951RA (en) 2008-10-20 2017-06-29 Abbvie Inc Viral inactivation during purification of antibodies
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
AU2011246502B2 (en) 2010-04-26 2014-08-28 Novartis Ag Improved cell cultivation process
BR112013018751B1 (pt) * 2010-12-28 2021-01-05 Chugai Seiyaku Kabushiki Kaisha (Chugai Pharmaceutical Co., Ltd.) método para modular o nível de componentes de homogeneidade de uma proteína, método para produzir uma proteína desejada, medicamento e método para preparação do mesmo
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
SG10201912621TA (en) * 2013-03-15 2020-02-27 Genentech Inc Cell culture compositions with antioxidants and methods for polypeptide production
JP6689189B2 (ja) * 2013-03-26 2020-04-28 コヒラス・バイオサイエンシズ・インコーポレイテッド タンパク質産生方法
WO2014182658A1 (en) * 2013-05-06 2014-11-13 Abbvie Inc. Compositions for cell culture and methods of using the same
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
USD759075S1 (en) * 2014-04-11 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
USD759076S1 (en) * 2014-04-18 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
JP6948942B2 (ja) * 2014-10-15 2021-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) * 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
EP3529350A1 (en) 2016-10-19 2019-08-28 H. Hoffnabb-La Roche Ag Method for producing an immunoconjugate
WO2018151819A1 (en) * 2017-02-17 2018-08-23 Lonza Ltd A method for producing biologic product variants
BR122023022045A2 (pt) * 2017-10-16 2024-01-16 Regeneron Pharmaceuticals, Inc. Métodos e sistemas para controlar condições de meio de cultura celular e para reduzir modificações pós-translação de uma proteína secretada
JP2022506413A (ja) * 2018-11-02 2022-01-17 ウーシー バイオロジクス アイルランド リミテッド 連続的採取を行い細胞流出を行わない強化灌流による細胞培養法
CA3130462A1 (en) * 2019-03-04 2020-09-10 Amgen Inc. In vivo reversibility of high molecular weight species
US11786605B2 (en) 2020-01-09 2023-10-17 Mersana Therapeutics, Inc. Site specific antibody-drug conjugates with peptide-containing linkers
WO2022254319A1 (en) * 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide
KR102682066B1 (ko) * 2021-10-12 2024-07-05 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법
WO2024163242A1 (en) * 2023-02-03 2024-08-08 Amgen Inc. Cell culture methods
CN118166053A (zh) * 2024-03-15 2024-06-11 通化安睿特生物制药股份有限公司 一种制备低o-糖基化水平的重组人白蛋白的方法
CN118006716B (zh) * 2024-03-15 2024-09-10 通化安睿特生物制药股份有限公司 制备高表达且低o-糖基化水平的重组人白蛋白的方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5610033A (en) 1990-04-25 1997-03-11 Novo Nordisk A/S Method of producing proteins with FVIII activity and/or FVIII derivatives
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP0571390B1 (en) * 1990-11-23 2000-03-08 Peptech Limited The delay, prevention and/or reversal of cell senescence
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
ATE363532T1 (de) 1991-03-01 2007-06-15 Dyax Corp Verfahren zur herstellung bindender miniproteine
ES2315612T3 (es) 1991-04-10 2009-04-01 The Scripps Research Institute Genotecas de receptores heterodimericos usando fagemidos.
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
SG47030A1 (en) 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
US5516964A (en) 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
CA2229043C (en) * 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6146847A (en) 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
KR20080059467A (ko) * 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
CA2318376A1 (en) 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
BR0010361A (pt) 1999-04-30 2003-06-10 Chiron Corp Seq ências genÈmicas de neisseria e uso destas
JP3090657B1 (ja) 1999-08-09 2000-09-25 伸子 蓮山 ゼオライト製造方法およびゼオライト製造装置
EP1103615A1 (en) 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
AUPR038200A0 (en) * 2000-09-26 2000-10-19 Beta Peptide Foundation Pty Ltd, The Compositions and methods for delaying, preventing, rejuvenating or reversing senescence
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US6544076B2 (en) 2001-07-10 2003-04-08 Alan L. Pocrass Dual function RJ connector
ES2344448T3 (es) * 2001-11-19 2010-08-27 Novo Nordisk A/S Proceso para preparar compuestos de insulina.
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
AU2003220529B2 (en) * 2002-03-27 2006-09-07 Immunex Corporation Methods for increasing polypeptide production
GB0208041D0 (en) 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
EP1520008B1 (en) 2002-07-09 2012-09-05 Baxter International Inc. Animal protein free media for cultivation of cells
PT1543106E (pt) 2002-07-15 2007-05-31 Immunex Corp Métodos e meios para controlar a sialilação de proteínas produzidas por células de mamíferos
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US7541164B2 (en) 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP1620457A2 (en) 2003-04-25 2006-02-01 Immunex Corporation Inducers of recombinant protein expression
CN1565631A (zh) * 2003-06-27 2005-01-19 上海中信国健药业有限公司 肿瘤坏死因子受体－免疫球蛋白的融合蛋白用于急性肺损伤药物的用途
RU2409591C2 (ru) 2003-10-27 2011-01-20 Вайет Удаление агрегатов с высокой молекулярной массой путем хроматографии на гидроксиапатитах
WO2005064013A1 (en) 2003-12-23 2005-07-14 Bart Janssen The use of carnosine metabolism-associated genes to determine genetic predisposition/susceptibility to diabetic nephropathy
DK2156852T3 (da) * 2004-07-07 2011-08-08 Coloplast As Kateter omfattende Estane 58212
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
EP1781684A4 (en) 2004-08-25 2008-05-21 Amprotein Corp NEW CHIMERE POLYPEPTIDE AND USE THEREOF
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7426440B2 (en) * 2004-09-24 2008-09-16 Nutritional Bioscience Ltd. Repair and protection factor scoring method for bioactive agents
US20070102622A1 (en) 2005-07-01 2007-05-10 Olsen Richard I Apparatus for multiple camera devices and method of operating same
WO2007011595A2 (en) 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
DE102005034616B4 (de) * 2005-07-18 2008-07-03 Elringklinger Ag Brennstoffzelleneinheit und Brennstoffzellenstapel
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
PT2495307T (pt) * 2006-07-13 2018-05-10 Wyeth Llc Produção do fator ix de coagulação com padrão melhorado de glicosilação
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
EP2188371B1 (en) 2007-08-09 2017-12-20 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
WO2023039771A1 (zh) 2021-09-15 2023-03-23 宁德时代新能源科技股份有限公司 电池单体、电池、用电装置、制备电池单体的方法及设备

Also Published As

Publication number Publication date
CA2685552A1 (en) 2008-10-30
AU2008242632A1 (en) 2008-10-30
CO6241165A2 (es) 2011-01-20
CN105039473A (zh) 2015-11-11
HK1142095A1 (zh) 2010-11-26
AU2008242633A1 (en) 2008-10-30
PL2139987T3 (pl) 2013-11-29
KR101540124B1 (ko) 2015-07-28
JP2014113161A (ja) 2014-06-26
PT2139986T (pt) 2017-11-14
IL201720A0 (en) 2011-08-01
ES2424217T9 (es) 2014-01-27
AU2008242633B2 (en) 2014-09-18
PA8777701A1 (es) 2008-11-19
TW200902708A (en) 2009-01-16
RU2478702C2 (ru) 2013-04-10
KR20100017211A (ko) 2010-02-16
PE20090731A1 (es) 2009-07-15
EP2139986A1 (en) 2010-01-06
CA2684727A1 (en) 2008-10-30
US20080274507A1 (en) 2008-11-06
CN101668845A (zh) 2010-03-10
RU2009139054A (ru) 2011-05-27
CA2685552C (en) 2016-02-23
CL2008001159A1 (es) 2008-11-03
KR20100016271A (ko) 2010-02-12
RU2009138226A (ru) 2011-05-27
DK2139987T3 (da) 2013-09-02
IL201720A (en) 2016-03-31
PA8778001A1 (es) 2008-11-19
EP2139987B1 (en) 2013-07-03
CO6241166A2 (es) 2011-01-20
HK1216261A1 (zh) 2016-10-28
DK2139986T3 (da) 2017-10-02
CN101668845B (zh) 2015-11-25
HUE034776T2 (en) 2018-02-28
EP2139987A1 (en) 2010-01-06
CN101679943A (zh) 2010-03-24
KR101560421B1 (ko) 2015-10-15
JP2010524504A (ja) 2010-07-22
CA2684727C (en) 2018-09-04
AR066238A1 (es) 2009-08-05
AR066239A1 (es) 2009-08-05
ZA200907426B (en) 2010-08-25
US9988662B2 (en) 2018-06-05
EP2139987B9 (en) 2013-11-13
PL2139986T3 (pl) 2018-01-31
JP2010524503A (ja) 2010-07-22
BRPI0810482A2 (pt) 2014-10-07
EP2139986B1 (en) 2017-09-06
IL201719A0 (en) 2011-08-01
AU2008242632B2 (en) 2013-11-28
PE20090153A1 (es) 2009-04-23
US12054762B2 (en) 2024-08-06
JP5557736B2 (ja) 2014-07-23
JP5881755B2 (ja) 2016-03-09
KR20140132016A (ko) 2014-11-14
IL201719A (en) 2015-09-24
WO2008131374A1 (en) 2008-10-30
PT2139987E (pt) 2013-08-22
MX2009011363A (es) 2009-11-05
SI2139987T1 (sl) 2013-09-30
TW200902709A (en) 2009-01-16
CL2008001156A1 (es) 2009-01-16
US20080269132A1 (en) 2008-10-30
MX2009011362A (es) 2009-11-05
ES2424217T3 (es) 2013-09-30
ES2646090T3 (es) 2017-12-12
SI2139986T1 (sl) 2017-11-30
BRPI0810511A2 (pt) 2014-10-07
WO2008131375A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
DK2139987T5 (da) Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
DK3118220T3 (da) Protein
DK3067064T3 (da) Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
DK2207428T3 (da) Fremgangsmåde til at fremstille laktosefri mælk
DK2231565T3 (da) Fremgangsmåder til fremstilling af clorerede carbonhydrider
DK2046819T3 (da) Fremgangsmåder til forøgelse af secernering af polypeptider med biologisk aktivitet
DK2046826T3 (da) Exendin-fusionsproteiner
BRPI0814971A2 (pt) Proteína
BRPI0807453A2 (pt) Preparação sólida
BRPI0910668A2 (pt) inibidores de proteína quinases
BRPI0812350A2 (pt) Conexão
DK2125048T3 (da) Præparat
DK2837348T3 (da) Kryokirurgiske fremgangsmåder
BRPI0814876A2 (pt) Análogos de pirona fosforilados e métodos
NO20060919L (no) Boyle til barnestol
NO2022038I1 (no) ropeginterferon alfa-2b
BRPI0913429A2 (pt) isolado de proteína de canola
DK1927646T3 (da) Odoriseringsmiddel med forbedret stabilitet
DK2276850T3 (da) Irx-2-modificeret fremstillingsfremgangsmåde
DE502007002482D1 (de) Injektor
FI20075156A0 (fi) Venttiili
FR2924101B1 (fr) Valve amelioree
NO20081658L (no) Festeanordning for stol
ES1065138Y (es) Chancla desechable
DK2219663T3 (da) Revers-protein